CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
OPERATING ACTIVITIES
Net loss	$ (663)	$ (2,771)
Non cash items:
Depreciation and amortization	179	157
Non-cash stock-based compensation	35	174
Reduction in JV Losses recognized	(946)
Change in other operating items:
Other current assets	143	308
Accounts payable	(5)	130
Other accrued liabilities	48	(151)
Cash flows used in operating activities	(1,209)	(2,153)
INVESTING ACTIVITIES
Cash flows provided by investing activities	0	0
FINANCING ACTIVITIES
Convertible Promissory Notes Payable	0	1,000
LipimetiX Development, Inc., Series B-1 Preferred Stock sale, net of issuance costs	946	0
Cash flows provided by financing activities	946	1,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(263)	(1,153)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	1,011	2,164
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 748	$ 1,011